Teva Offers $57.5 Million Upfront for BioXcel Assets in Chapter 11 Sale

Teva Pharmaceutical Industries, through its Teva Pharmaceuticals International GmbH subsidiary, has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics’ assets, offering $57.5 million in upfront cash as the neuroscience developer moves through Chapter 11 in Delaware. The proposed sale would give Teva control of IGALMI, BioXcel’s approved dexmedetomidine sublingual film, along with the related BXCL501 program that is under U.S. Food and Drug Administration review for possible at-home use in adults with agitation associated with schizophrenia or bipolar I or II disorder.

The agreement does not guarantee that Teva will ultimately acquire the assets. BioXcel opened a court-supervised sale process after filing voluntary Chapter 11 petitions on August 27, and other bidders can submit higher or otherwise better offers. Teva’s bid establishes the floor for the auction, with completion requiring bankruptcy-court approval and satisfaction of other conditions.

The consideration also needs to be described carefully because the two companies’ August 28 disclosures present the contingent payments differently. BioXcel’s Form 8-K says Teva would pay $57.5 million upfront, assume specified liabilities and provide up to $67.5 million of development milestone payments tied to the outcome and timing of the pending supplemental New Drug Application. The filing separately says BioXcel may be entitled to as much as $20 million of commercial milestone payments, depending on approval timing and post-closing net sales. Teva’s announcement, by contrast, describes $57.5 million upfront plus up to $67.5 million in additional contingent payments, including approval-timing and sales milestones. Until the full asset purchase agreement is filed publicly, the clearest common figure is the $57.5 million upfront bid plus contingent payments rather than a single maximum purchase price.

A bankruptcy auction, not a completed acquisition

BioXcel and its subsidiaries OnkosXcel Therapeutics and OnkosXcel Employee Holdings filed Chapter 11 petitions in the U.S. Bankruptcy Court for the District of Delaware. The company said the cases are intended to support a sale of all or substantially all of its assets to the highest or otherwise best bidder. BioXcel is continuing to operate as a debtor in possession while the court considers first-day requests and the proposed sale procedures.

Under the proposed Section 363 process, Teva’s offer serves as the minimum bid for substantially all of the debtors’ assets. The filing says BioXcel asked the court to approve bidding procedures, designate Teva as the stalking-horse bidder and authorize bid protections, while preserving the ability to accept a higher or otherwise better offer. If Teva is selected as the successful bidder, the sale would still depend on the court approving the purchase and on the parties meeting the agreement’s closing conditions.

The filing also sets an October 30, 2026 outside date as one of the circumstances that can trigger termination rights if the sale has not been completed. That timetable gives the bankruptcy process a relatively short runway, but it does not remove uncertainty around rival bids, court rulings or the regulatory status of BXCL501. Teva has said that if it is not the successful bidder, it would be entitled to a break-up fee and expense reimbursement subject to the agreement and court approval.

BioXcel entered Chapter 11 with little liquidity

The bankruptcy filing follows months of tightening financial constraints. In its second-quarter Form 10-Q, BioXcel reported $13.8 million of cash, cash equivalents and restricted cash at June 30 and said that amount was expected to fund operations and liquidity needs only through the end of August. The same filing showed about $107.2 million of aggregate principal indebtedness under its senior secured credit facility.

Those pressures became more visible in the days before the bankruptcy case. On August 24, BioXcel entered into a fourteenth amendment to its credit agreement with lenders led administratively by Oaktree Fund Administration. The lenders provided another $1.25 million term loan, for which BioXcel paid a $250,000 upfront fee, and reduced the minimum cash-liquidity covenant to $250,000. The amendment also extended to August 31 the deadline for BioXcel to enter into an acceptable agreement that would repay its obligations or provide another capital solution.

Chapter 11 gives the company a framework to keep operating while it runs the sale. BioXcel’s August 28 announcement said it had secured a commitment for $19 million of debtor-in-possession financing from existing secured lenders. Its Form 8-K gives more detail, describing up to $19 million of new-money term-loan commitments in two potential $9.5 million draws, plus up to $58.25 million of roll-up loans that would convert a portion of prepetition obligations into the bankruptcy financing. Court approval is required for the financing.

BioXcel said IGALMI remains commercially available and that it intends to continue supporting patients, prescribers and trade partners during the case. The bankruptcy filing therefore does not amount to an immediate shutdown of the commercial product, although the company’s longer-term ownership and capital structure are now tied to the court-supervised process.

BXCL501 gives Teva a near-term FDA catalyst

The asset at the center of Teva’s interest is dexmedetomidine sublingual film. IGALMI is already approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults when administered under the supervision of a healthcare provider. BioXcel is seeking an expanded label for at-home, or outpatient, use of BXCL501 in the same adult patient population.

The FDA has assigned November 14, 2026 as the target action date for the supplemental application. Teva says the product could become the first FDA-approved at-home treatment for this form of agitation if the application is cleared. That potential label expansion also explains why the bid contains milestone payments tied to both the timing of approval and later commercial performance. Regulatory success is not guaranteed, and BioXcel states that the safety and efficacy of BXCL501 for investigational uses have not been established.

For Teva, the proposed purchase fits a broader effort to expand its innovative neuroscience portfolio. In second-quarter results released in July, the company said its three key innovative brands generated more than $1 billion of revenue in the quarter, with UZEDY, its long-acting risperidone product, generating $77 million. Teva has described neuroscience as one of the areas it is strengthening under its “Pivot to Growth” strategy, making BXCL501 a potential addition to an existing psychiatry franchise rather than a move into an entirely new therapeutic field.

The immediate milestones are now split between the bankruptcy court and the FDA. BioXcel must obtain approval for the bidding and sale process, competing buyers still have an opportunity to challenge Teva’s floor bid, and any eventual transfer of the assets remains subject to the court and closing conditions. Separately, the FDA’s November 14 target date will determine whether the at-home indication that underpins much of BXCL501’s strategic appeal can move forward on the current schedule.